Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ).
Shanghai Haohai Biological Technology Co., Ltd. has announced its annual results for the year ended 31 December 2024, declaring a final ordinary cash dividend of RMB 0.6 per share. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders, although specific details regarding the payment date and exchange rate are yet to be disclosed.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development and production of biological materials and medical devices. The company is known for its innovative solutions in the healthcare sector, catering to a diverse market with a range of products.
YTD Price Performance: 8.44%
Average Trading Volume: 465,565
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$13.97B
See more data about 6826 stock on TipRanks’ Stock Analysis page.